Privium Fund Management B.V. Invests $4.54 Million in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Privium Fund Management B.V. bought a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 325,709 shares of the company's stock, valued at approximately $4,537,000. Arcutis Biotherapeutics makes up 1.0% of Privium Fund Management B.V.'s investment portfolio, making the stock its 21st biggest holding. Privium Fund Management B.V. owned 0.28% of Arcutis Biotherapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the stock. Suvretta Capital Management LLC raised its stake in shares of Arcutis Biotherapeutics by 7.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 10,721,511 shares of the company's stock valued at $99,710,000 after purchasing an additional 717,019 shares during the period. Fishman Jay A Ltd. MI increased its position in shares of Arcutis Biotherapeutics by 28.3% during the 4th quarter. Fishman Jay A Ltd. MI now owns 536,400 shares of the company's stock worth $7,472,000 after purchasing an additional 118,400 shares during the last quarter. Rubric Capital Management LP raised its stake in shares of Arcutis Biotherapeutics by 11.7% during the 3rd quarter. Rubric Capital Management LP now owns 10,966,672 shares of the company's stock worth $101,990,000 after purchasing an additional 1,150,000 shares in the last quarter. Algert Global LLC raised its stake in shares of Arcutis Biotherapeutics by 595.9% during the 3rd quarter. Algert Global LLC now owns 72,480 shares of the company's stock worth $674,000 after purchasing an additional 62,065 shares in the last quarter. Finally, Barclays PLC boosted its holdings in shares of Arcutis Biotherapeutics by 45.8% in the 3rd quarter. Barclays PLC now owns 253,392 shares of the company's stock valued at $2,356,000 after buying an additional 79,579 shares during the last quarter.

Remove Ads

Arcutis Biotherapeutics Price Performance

Shares of Arcutis Biotherapeutics stock traded up $0.24 during trading on Friday, reaching $17.01. 1,973,627 shares of the company's stock were exchanged, compared to its average volume of 2,390,697. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.38 and a current ratio of 2.46. Arcutis Biotherapeutics, Inc. has a 1-year low of $6.99 and a 1-year high of $17.70. The company has a market cap of $2.02 billion, a P/E ratio of -9.50 and a beta of 1.48. The firm's 50-day moving average price is $13.67 and its 200 day moving average price is $12.04.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.19. The firm had revenue of $71.36 million during the quarter, compared to analysts' expectations of $60.52 million. Arcutis Biotherapeutics had a negative net margin of 140.97% and a negative return on equity of 119.11%. As a group, research analysts anticipate that Arcutis Biotherapeutics, Inc. will post -1.33 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Masaru Matsuda sold 8,338 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $12.70, for a total transaction of $105,892.60. Following the transaction, the insider now owns 178,692 shares of the company's stock, valued at $2,269,388.40. This represents a 4.46 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Patrick Burnett sold 2,819 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $13.03, for a total value of $36,731.57. Following the transaction, the insider now owns 167,043 shares in the company, valued at approximately $2,176,570.29. This trade represents a 1.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 56,290 shares of company stock worth $775,350 in the last 90 days. Insiders own 9.50% of the company's stock.

Analyst Ratings Changes

Several research firms have issued reports on ARQT. The Goldman Sachs Group upped their price target on shares of Arcutis Biotherapeutics from $13.00 to $15.00 and gave the stock a "neutral" rating in a research report on Thursday, February 27th. Needham & Company LLC reiterated a "buy" rating and issued a $20.00 target price on shares of Arcutis Biotherapeutics in a research note on Wednesday, February 26th. HC Wainwright restated a "buy" rating and issued a $19.00 price objective on shares of Arcutis Biotherapeutics in a research note on Wednesday, February 26th. Mizuho increased their price objective on shares of Arcutis Biotherapeutics from $20.00 to $21.00 and gave the company an "outperform" rating in a research report on Wednesday, February 26th. Finally, Jefferies Financial Group lifted their target price on shares of Arcutis Biotherapeutics from $16.00 to $19.00 and gave the stock a "buy" rating in a report on Tuesday, March 11th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $18.80.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.